Ftse Mib
33.746,66
0,00%
DAX
17.932,17
-1,10%
S&P 500
5.018,39
-0,34%
NASDAQ Composite
15.605,48
-0,33%
Bitcoin
57.291,61
-1,62%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Ionis Pharmaceuticals Inc (IONS) Ionis Pharmaceuticals Inc (IONS) Notizie

IONS

Ionis Pharmaceuticals (IONS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IONS
DataOraFonteTitoloSimboloCompagnia
25/04/202413:00PR Newswire (US)Ionis Publishes 2023 Corporate Responsibility ReportNASDAQ:IONSIonis Pharmaceuticals Inc
23/04/202413:05PR Newswire (US)Ionis to hold first quarter 2024 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
07/04/202415:48PR Newswire (US)Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
01/04/202413:05PR Newswire (US)Ionis to present at upcoming investor conferencesNASDAQ:IONSIonis Pharmaceuticals Inc
28/03/202412:05PR Newswire (US)Ionis to hold olezarsen Phase 3 data webcastNASDAQ:IONSIonis Pharmaceuticals Inc
25/03/202413:18PR Newswire (US)Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meetingNASDAQ:IONSIonis Pharmaceuticals Inc
13/03/202412:00PR Newswire (US)Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASHNASDAQ:IONSIonis Pharmaceuticals Inc
06/03/202413:30GlobeNewswire Inc.New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene TherapyNASDAQ:IONSIonis Pharmaceuticals Inc
05/03/202401:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
29/02/202415:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
29/02/202415:05PR Newswire (US)Ionis announces new chief global product strategy officer to lead next phase of commercial growthNASDAQ:IONSIonis Pharmaceuticals Inc
21/02/202413:00PR Newswire (US)Ionis reports fourth quarter and full year 2023 financial resultsNASDAQ:IONSIonis Pharmaceuticals Inc
20/02/202416:39Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
16/02/202422:34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
15/02/202413:00PR Newswire (US)Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
14/02/202416:04Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IONSIonis Pharmaceuticals Inc
13/02/202412:09Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
08/02/202413:00PR Newswire (US)Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathyNASDAQ:IONSIonis Pharmaceuticals Inc
07/02/202413:05PR Newswire (US)Ionis to hold fourth quarter and full year 2023 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
22/01/202413:00PR Newswire (US)Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedemaNASDAQ:IONSIonis Pharmaceuticals Inc
08/01/202413:03PR Newswire (US)Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseasesNASDAQ:IONSIonis Pharmaceuticals Inc
22/12/202301:38Dow Jones NewsIonis Pharmaceuticals, AstraZeneca Get FDA Approval for Rare Genetic Disease TreatmentNASDAQ:IONSIonis Pharmaceuticals Inc
22/12/202300:55PR Newswire (US)WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosisNASDAQ:IONSIonis Pharmaceuticals Inc
20/12/202313:05PR Newswire (US)Ionis to present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:IONSIonis Pharmaceuticals Inc
18/12/202322:56Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
18/12/202322:01PR Newswire (US)Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedemaNASDAQ:IONSIonis Pharmaceuticals Inc
14/12/202322:05PR Newswire (US)Ionis announces the appointment of Michael Yang to Board of DirectorsNASDAQ:IONSIonis Pharmaceuticals Inc
24/11/202319:31Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:IONSIonis Pharmaceuticals Inc
16/11/202314:00GlobeNewswire Inc.Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental EpilepsiesNASDAQ:IONSIonis Pharmaceuticals Inc
11/11/202317:30PR Newswire (US)Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IONS

La tua Cronologia

BIT
STLAM
Stellantis NV
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENI
Eni
BIT
STMMI
ST Microelectronics
BIT
RACE
Ferrari NV
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
TEN
Tenaris
BIT
TIT
Telecom Italia
BIT
LDO
Leonardo
BIT
SPM
Saipem
BIT
SRG
Snam
BIT
FBK
Finecobank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network